Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Signs Distribution Deal For Aura in UK and Ireland

Premium

Verisante Technology said this week that it has signed an exclusive agreement with Frontière Médicale EUROPE for distribution of its Verisante Aura skin cancer detection device in the UK and Ireland.

With the agreement, Verisante now has distribution agreements for the Aura in Canada, Germany, Austria, Liechtenstein, Switzerland, the UK, and Ireland. The company began sales of the device at the beginning of the year, and recognized $235,000 in revenue from it for the quarter ended March 21, 2013.

The Aura uses Raman spectroscopy to measure the levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions to distinguish between benign and malignant lesions. By comparing the patterns of spectra generated by the device, clinicians can differentiate between the two.

According to Verisante, there are more than 650 dermatologists in Ireland and the UK, with the rate of skin cancer in Ireland almost doubling in the last 10 years.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.